CN106831485A - Two(4 methoxybenzylidenes)The preparation and use of the diamines of butane 1,4 - Google Patents
Two(4 methoxybenzylidenes)The preparation and use of the diamines of butane 1,4 Download PDFInfo
- Publication number
- CN106831485A CN106831485A CN201710195193.4A CN201710195193A CN106831485A CN 106831485 A CN106831485 A CN 106831485A CN 201710195193 A CN201710195193 A CN 201710195193A CN 106831485 A CN106831485 A CN 106831485A
- Authority
- CN
- China
- Prior art keywords
- crystal
- schiff base
- butane
- fluorescent
- base dimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract 3
- -1 methoxybenzylidenes Chemical class 0.000 title abstract description 4
- 239000001273 butane Substances 0.000 title 1
- 150000004985 diamines Chemical class 0.000 title 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 title 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 claims abstract description 26
- 239000000539 dimer Substances 0.000 claims abstract description 15
- 239000002262 Schiff base Substances 0.000 claims abstract description 12
- 150000004753 Schiff bases Chemical class 0.000 claims abstract description 12
- 238000002844 melting Methods 0.000 claims abstract description 8
- 230000008018 melting Effects 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 5
- 201000005202 lung cancer Diseases 0.000 claims abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 19
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 3
- 238000012742 biochemical analysis Methods 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000006081 fluorescent whitening agent Substances 0.000 claims description 2
- 239000000990 laser dye Substances 0.000 claims description 2
- 239000012860 organic pigment Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 5
- QVYARBLCAHCSFJ-UHFFFAOYSA-N butane-1,1-diamine Chemical compound CCCC(N)N QVYARBLCAHCSFJ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1014—Carbocyclic compounds bridged by heteroatoms, e.g. N, P, Si or B
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Emergency Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种丁基连接的西弗碱二聚体晶体,外观呈无色透明块状,熔点76.6‑77.2℃,分子式C20H24N2O2,分子量为324.42,化学名为:(N1E,N4E)‑N1,N4‑二(4‑甲氧基苯亚甲基)丁烷‑1,4‑二胺,其结构如下:该晶体属单斜晶系,P21/n空间群,α=γ=90°,β=90.509(5)°,Z=2。该西弗碱二聚体晶体制备方法简单,在400~500nm之间有强的荧光发射。该西弗碱二聚体晶体对肺癌细胞有温和的抗肿瘤活性。The invention relates to a butyl-linked Schiff base dimer crystal, which has a colorless and transparent block shape, a melting point of 76.6-77.2°C, a molecular formula of C 20 H 24 N 2 O 2 , a molecular weight of 324.42, and a chemical name of: ( N 1 E,N 4 E)-N 1 ,N 4 -bis(4-methoxybenzylidene)butane-1,4-diamine, the structure of which is as follows: The crystal belongs to monoclinic system, P2 1 /n space group, α=γ=90°, β=90.509(5)°, Z=2. The preparation method of the Schiff base dimer crystal is simple, and has strong fluorescence emission between 400-500 nm. The schiff base dimer crystal has mild antitumor activity on lung cancer cells.
Description
技术领域technical field
本发明涉及有机合成、光学材料和药物化学领域,使用较简单的原料和方法一步合成目标产物。The invention relates to the fields of organic synthesis, optical materials and medicinal chemistry, and uses relatively simple raw materials and methods to synthesize target products in one step.
背景技术Background technique
对称性在生命活动中扮演着重要的角色,因此二聚体在天然产物中是一种普遍存在的结构类型。在材料化学领域,二聚体结构经常被用于光电材料、超分子材料、功能染料、荧光材料等新型材料的构建中;以有机二聚体结构为基础的荧光材料被广泛应用于光学电子器件、DNA诊断、光化学传感器、有机颜料、染料、荧光增白剂、光氧化剂、荧光涂料、激光染料、有机电致发光器件(ELD)化学及生化分析、太阳能捕集器、防伪标记、药物示踪及激光等领域;在药物化学领域,二聚体往往比相应的单体表现出更好的活性;具有优异性能的新型二聚体材料的设计和合成一直是材料学家和药物化学家努力的方向。Symmetry plays an important role in life activities, so dimers are a ubiquitous structural type in natural products. In the field of material chemistry, dimer structures are often used in the construction of new materials such as optoelectronic materials, supramolecular materials, functional dyes, and fluorescent materials; fluorescent materials based on organic dimer structures are widely used in optical and electronic devices , DNA diagnostics, photochemical sensors, organic pigments, dyes, fluorescent whitening agents, photooxidants, fluorescent coatings, laser dyes, organic electroluminescent devices (ELD) chemical and biochemical analysis, solar collectors, anti-counterfeiting marks, drug tracers and laser and other fields; in the field of medicinal chemistry, dimers often show better activity than corresponding monomers; the design and synthesis of new dimer materials with excellent properties have always been the efforts of materials scientists and medicinal chemists direction.
西弗碱是一种结构比较特殊的化合物,根据引入基团的不同可以合成不同种类的西弗碱;西弗碱在医学、催化、分析化学、腐蚀以及光致变色等领域都有重要应用,例如,在医学领域,西弗碱具有抑菌、杀菌、抗肿瘤、抗病毒的生物活性;在光学材料领域,由于其富电子和刚性平面的特点,使其具有良好的荧光性能及非线性光学性质;考虑到西弗碱二聚体的连接链本身可以有丰富的变化,其在光学材料和药物化学领域也具有良好的应用前景。Schiff base is a compound with a relatively special structure. Different types of Schiff bases can be synthesized according to the different groups introduced; Schiff bases have important applications in the fields of medicine, catalysis, analytical chemistry, corrosion, and photochromism. For example, in the medical field, Schiff base has antibacterial, bactericidal, antitumor, and antiviral biological activities; in the field of optical materials, due to its electron-rich and rigid plane characteristics, it has good fluorescence properties and nonlinear optical properties. Properties; Considering that the connecting chain of the Schiff base dimer itself can have abundant changes, it also has good application prospects in the fields of optical materials and medicinal chemistry.
发明内容Contents of the invention
1、结构表征1. Structural characterization
本发明的内容是通过多种方法制备得到了一种以丁基(即-(CH2)4-)为连接链的西弗碱共轭二聚体晶体,该二聚体晶体的结构及有关表征参数如下:The content of the present invention is that a kind of Schiff base conjugated dimer crystal with butyl (i.e. -(CH 2 ) 4 -) as the connecting chain has been prepared by various methods. The structure of the dimer crystal and related The characterization parameters are as follows:
该化合物外观呈无色透明块状晶体,熔点76.6-77.2℃,分子式C20H24N2O2,分子量为324.42,化学名为:(N1E,N4E)-N1,N4-二(4-甲氧基苯亚甲基)丁烷-1,4-二胺,英文系统命名为:(N1E,N4E)-N1,N4-bis(4-methoxybenzylidene)butane-1,4-diamine,其结构如下:The appearance of the compound is colorless transparent block crystal, melting point 76.6-77.2℃, molecular formula C 20 H 24 N 2 O 2 , molecular weight 324.42, chemical name: (N 1 E,N 4 E)-N 1 ,N 4 -Bis(4-methoxybenzylidene)butane-1,4-diamine, the English system name is: (N 1 E,N 4 E)-N 1 ,N 4 -bis(4-methoxybenzylidene) Butane-1,4-diamine, its structure is as follows:
元素分析表明,该二聚体C、H、N的百分含量分别为74.16%、7.53%和8.75%(按分子式C20H24N2O2计算的理论值分别为74.04%、7.46%和8.64%);单晶结构分析表明,其结晶为单斜晶系,P21/n空间群,α=γ=90°,β=90.509(5)°,Z=2,附图1、附图2分别是该化合物的热椭球晶体结构图和晶体结构堆积图,有关的1HNMR谱、13CNMR谱分别见附图3和附图4。Elemental analysis shows that the percentages of dimer C, H, and N are 74.16%, 7.53%, and 8.75% (theoretical values calculated by molecular formula C 20 H 24 N 2 O 2 are 74.04%, 7.46%, and 8.64%); single crystal structure analysis shows that its crystal is monoclinic, P2 1 /n space group, α=γ=90°, β=90.509(5)°, Z=2, accompanying drawings 1 and 2 are the thermal ellipsoidal crystal structure diagram and crystal structure packing diagram of the compound respectively, and the relevant 1 HNMR spectrum and 13 CNMR spectrum are shown in accompanying drawings 3 and 4 respectively.
2、合成方法2. Synthesis method
该化合物合成方法上的特征在于:以对甲氧基苯甲醛和丁二胺为原料,采用溶液合成或固相合成法。步骤如下:The synthesis method of the compound is characterized in that: p-methoxybenzaldehyde and butanediamine are used as raw materials, and solution synthesis or solid phase synthesis is adopted. Proceed as follows:
1)将对甲氧基苯甲醛和丁二胺分别溶于合适的有机溶剂中,然后按一定的摩尔比混合,在一定的温度下搅拌反应一定时间;也可以不用有机溶剂,直接混合两种反应物,研磨反应。1) Dissolve p-methoxybenzaldehyde and butylenediamine in suitable organic solvents respectively, then mix them in a certain molar ratio, stir and react at a certain temperature for a certain period of time; you can also directly mix the two without organic solvents Reactants, grinding reactions.
2)液相反应时,将得到的溶液采用一定的方法除去大部分溶剂,可得到粉末或结晶状物,即为目标产物;固相反应时,研磨一定时间可得目标产物。2) During the liquid phase reaction, remove most of the solvent from the obtained solution by a certain method to obtain powder or crystal, which is the target product; during the solid phase reaction, grind for a certain period of time to obtain the target product.
3)目标产物可以在合适的有机溶剂中重结晶以纯化产品。3) The target product can be recrystallized in a suitable organic solvent to purify the product.
优选的,上述反应溶剂或重结晶用溶剂选自:甲醇、乙酸乙酯、二氯甲烷、乙醇、乙腈、丙酮、氯仿、四氢呋喃、甲苯、N,N-二甲基甲酰胺。Preferably, the above-mentioned reaction solvent or solvent for recrystallization is selected from methanol, ethyl acetate, dichloromethane, ethanol, acetonitrile, acetone, chloroform, tetrahydrofuran, toluene, and N,N-dimethylformamide.
优选的,对甲氧基苯甲醛和丁二胺的反应摩尔比为1:2至4:1。Preferably, the reaction molar ratio of p-methoxybenzaldehyde and butanediamine is 1:2 to 4:1.
优选的,所述反应温度为室温至加热回流。Preferably, the reaction temperature is from room temperature to heating to reflux.
优选的,所述反应时间为:0.5-12小时。Preferably, the reaction time is 0.5-12 hours.
优选的,所述除去溶剂的方法为自然挥发或常/减压蒸馏。Preferably, the method for removing the solvent is natural volatilization or atmospheric/vacuum distillation.
本发明的有益效果是:能够以比较简单的步骤和反应物一步合成比较复杂的功能分子材料,并且分离方法简单。The beneficial effect of the invention is that relatively complex functional molecular materials can be synthesized in one step with relatively simple steps and reactants, and the separation method is simple.
3、紫外和荧光性质。3. Ultraviolet and fluorescent properties.
在10-5mol/L乙醇溶液中测试本化合物的紫外光谱,发现其在211nm和268nm处有紫外吸收峰,如附图5所示;通过Gaussian03软件用TD-DFT理论,在b3lyp/6-311+g(d,p)方法/基组下计算了该化合物的紫外光谱,计算结果列于附图6;可以发现,计算所得谱图与实验结果吻合的很好,如计算所得两个主要强吸收峰分别位于219nm和270nm,与实验结果仅相差8nm和2nm;借助轨道分析发现,这两个吸收峰均是由π→π*跃迁产生的。Test the ultraviolet spectrum of this compound in 10 -5 mol/L ethanol solution, find that it has ultraviolet absorption peak at 211nm and 268nm place, as shown in accompanying drawing 5; Use TD-DFT theory by Gaussian03 software, in b3lyp/6- The UV spectrum of the compound was calculated under the 311+g(d,p) method/basis set, and the calculated results are shown in accompanying drawing 6; it can be found that the calculated spectra are in good agreement with the experimental results, as the calculated two main The strong absorption peaks are located at 219nm and 270nm, respectively, which are only 8nm and 2nm different from the experimental results; with the help of orbital analysis, it is found that these two absorption peaks are generated by the π→π* transition.
在10-5mol/L乙醇溶液中,用波长分别为351nm和368nm的紫外光激发,测试本化合物的荧光性质,发现其在400~500nm之间有强的荧光发射,荧光光谱见附图7;用紫外灯照射,肉眼可见蓝色荧光。In 10 -5 mol/L ethanol solution, excited by ultraviolet light with wavelengths of 351nm and 368nm respectively, the fluorescence properties of this compound were tested, and it was found that it had strong fluorescence emission between 400-500nm, and the fluorescence spectrum is shown in Figure 7 ; Irradiated by ultraviolet light, blue fluorescence is visible to the naked eye.
值得注意的是,该二聚体化合物已在多篇文献中被报道合成,如下列文献:a)S.Alina,S.Cristian,K.Tadeshige,N.Satoko,M.Yoshiharu,Y.Tomoko,M.Keisuke,T.Masashi,J.Chem.Soc.Perkin Trans.1(2001)2071-2078(报道熔点为116-117℃);b)M.S.Singh,A.K.Singh,Pratibha Singh,Ruchi Jain,Org.Prep.Proced.Int.NewJ.Org.Synthesis 37(2005)173-177(报道熔点为108-109℃);c)H.Temel,Cakir,H._I.U_gras,Russ.J.Inorg.Chem.46(2001) 1846-1850(报道熔点为105℃);d)Y.Goek,E.Cetinkaya,Turk.J.Chem.28(2004)157-162(报道熔点为117-118℃),但是至今未见有人得到该化合物的高纯单晶,因此文献报道的熔点与我们得到的晶体都不相同;我们对比了未结晶纯化的初产品和重结晶后的晶体的荧光性质,发现二者的荧光强度差别很大,测试同样质量的固体荧光,晶体的荧光强度大概是初产品的两倍以上;用紫外灯照射,初产品无法用肉眼观察到明显的荧光,即使增加固体用量,其荧光强度也远远不如晶体状态。It is worth noting that the dimer compound has been reported in many documents, such as the following documents: a) S.Alina, S.Cristian, K.Tadeshige, N.Satoko, M.Yoshiharu, Y.Tomoko, M. Keisuke, T. Masashi, J. Chem. Soc. Perkin Trans. 1 (2001) 2071-2078 (reported melting point is 116-117°C); b) MS Singh, AK Singh, Pratibha Singh, Ruchi Jain, Org. Prep. Proced.Int.NewJ.Org.Synthesis 37(2005) 173-177 (reported melting point 108-109°C); c) H.Temel, Cakir, H._I.U_gras, Russ.J.Inorg.Chem.46(2001) 1846-1850 (reported melting point is 105°C); d) Y.Goek, E.Cetinkaya, Turk.J.Chem.28(2004 ) 157-162 (the reported melting point is 117-118°C), but no one has obtained a high-purity single crystal of this compound so far, so the melting point reported in the literature is different from the crystal we obtained; we compared the uncrystallized and purified primary The fluorescent properties of the product and the crystal after recrystallization, found that the fluorescence intensity of the two is very different. When testing the solid fluorescence of the same quality, the fluorescence intensity of the crystal is more than twice that of the original product; when irradiated with ultraviolet light, the original product cannot be used. Obvious fluorescence is observed with the naked eye, and even if the amount of solid is increased, the fluorescence intensity is far less than that of the crystal state.
4、体外抗肿瘤活性。4. Antitumor activity in vitro.
将处于对数期生长的A549肺癌细胞,用0.25%胰酶消化细胞,使其成为单细胞,用含10%胎牛血清的F12K培养液制成浓度为1.25×107个/L的单细胞悬液,将细胞接种于96孔培养板中,每孔200μL(每孔2.5×103个细胞)。将96孔细胞培养板置于CO2培养箱中,在37℃,5%CO2条件下,培养48h。Digest the A549 lung cancer cells in the logarithmic phase with 0.25% trypsin to make them single cells, and use F12K culture medium containing 10% fetal bovine serum to make single cells with a concentration of 1.25× 107 cells/L Suspension, the cells were seeded in a 96-well culture plate, 200 μL per well (2.5×10 3 cells per well). The 96-well cell culture plate was placed in a CO 2 incubator at 37°C and 5% CO 2 for 48 hours.
当孔内细胞长满(90%满即可)时,按实验分组加入不同剂量的本西弗碱溶液(200μL/孔),使待测化合物的终浓度分别为5μM、10μM、50μM、100μM、200μM,每组设3个复孔,培养96h。When the cells in the wells are overgrown (90% full), add different doses of Bencifer base solution (200 μL/well) according to the experimental grouping, so that the final concentrations of the compounds to be tested are 5 μM, 10 μM, 50 μM, 100 μM, 200μM, set 3 duplicate wells in each group, and culture for 96h.
各个孔中分别加入20μL浓度为0.5g/L的MTT,继续培养4h,使MTT还原为甲瓒(Formazan)。吸出全部上清液后,每孔加入200μL的DMSO,震摇15min,使甲瓒充分溶解后,运用酶联免疫检测仪测定490nm处的吸光度(OD值)。然后按照下式进行计算:20 μL of MTT at a concentration of 0.5 g/L was added to each well, and culture was continued for 4 hours to reduce MTT to formazan. After all the supernatant was sucked out, 200 μL of DMSO was added to each well and shaken for 15 min to fully dissolve the formazan, and the absorbance (OD value) at 490 nm was measured with an enzyme-linked immunosorbent assay. Then calculate according to the following formula:
细胞抑制率%=(对照组OD值-实验组OD值)/对照组OD值×100%Cell inhibition rate%=(OD value of control group-OD value of experimental group)/OD value of control group×100%
测试结果表明,该西弗碱对肺癌细胞A549的IC50(药物的半数抑制浓度)为207.0μM,这表明该化合物对肺癌细胞具有温和的抑制效果。The test results showed that the IC50 (half inhibitory concentration of the drug) of the Schiff base on the lung cancer cell A549 was 207.0 μM, which indicated that the compound had a mild inhibitory effect on the lung cancer cell.
具体实施方式detailed description
为了更好的理解本发明内容,下面通过一个具体实施例进一步说明本发明的技术方案:In order to better understand the content of the present invention, the technical solution of the present invention is further described below through a specific embodiment:
实施例1。Example 1.
称取对甲氧基苯甲醛1.36g(0.01mol)溶于30mL无水乙醇中,加热搅拌至全部溶解,加入丁二胺0.44g(0.005mol),搅拌下加热回流6小时,冷至室温后过滤,滤液置于烧杯中静置挥发,可得大量晶体状沉淀,将所得沉淀过滤后得初产品,此初产品可用甲醇重结晶,得无色块状晶体,即为目标产物。Weigh 1.36g (0.01mol) of p-methoxybenzaldehyde and dissolve it in 30mL of absolute ethanol, heat and stir until completely dissolved, add 0.44g (0.005mol) of butanediamine, heat and reflux under stirring for 6 hours, and cool to room temperature Filtrate, put the filtrate in a beaker and let it stand for volatilization, and a large amount of crystal-like precipitates can be obtained. After filtering the obtained precipitates, the initial product can be obtained. The initial product can be recrystallized with methanol to obtain colorless blocky crystals, which is the target product.
实施例2。Example 2.
称取对甲氧基苯甲醛1.36g(0.01mol),加入丁二胺0.44g(0.005mol),常温下研磨8小时,得糊状物,然后加入20ml无水乙醇,加热溶解,冷却后得无色块状晶体,即为目标产物,重结晶可使产品纯化。Weigh 1.36g (0.01mol) of p-methoxybenzaldehyde, add 0.44g (0.005mol) of butanediamine, and grind for 8 hours at room temperature to obtain a paste, then add 20ml of absolute ethanol, heat to dissolve, and cool to obtain Colorless blocky crystals are the target product, and recrystallization can purify the product.
附图说明Description of drawings
附图1是目标化合物的晶体结构图,椭球概率30%。Accompanying drawing 1 is the crystal structure figure of target compound, and the probability of ellipsoid is 30%.
附图2是目标化合物的晶体结构堆积图,沿a轴方向观察。Accompanying drawing 2 is the crystal structure stacking diagram of the target compound, observed along the a-axis direction.
附图3是目标化合物的1HNMR谱图。Accompanying drawing 3 is the 1 HNMR spectrogram of the target compound.
附图4是目标化合物的13CNMR谱图。Accompanying drawing 4 is the 13 CNMR spectrogram of target compound.
附图5是目标化合物的紫外光谱图(实验结果)。Accompanying drawing 5 is the ultraviolet spectrogram (experimental result) of target compound.
附图6是目标化合物的紫外光谱图(Gaussian 03计算结果)。Accompanying drawing 6 is the ultraviolet spectrogram (Gaussian 03 calculation result) of target compound.
附图7是目标化合物的荧光光谱图(实验结果)。Accompanying drawing 7 is the fluorescence spectrogram (experimental result) of target compound.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710195193.4A CN106831485A (en) | 2017-03-29 | 2017-03-29 | Two(4 methoxybenzylidenes)The preparation and use of the diamines of butane 1,4 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710195193.4A CN106831485A (en) | 2017-03-29 | 2017-03-29 | Two(4 methoxybenzylidenes)The preparation and use of the diamines of butane 1,4 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106831485A true CN106831485A (en) | 2017-06-13 |
Family
ID=59142410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710195193.4A Pending CN106831485A (en) | 2017-03-29 | 2017-03-29 | Two(4 methoxybenzylidenes)The preparation and use of the diamines of butane 1,4 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106831485A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6310721A (en) * | 1987-03-19 | 1988-01-18 | Rikagaku Kenkyusho | anticancer drug |
KR20100023679A (en) * | 2008-08-22 | 2010-03-04 | 건국대학교 산학협력단 | Use in anti-cancer agent of [(meso-bis(o-hydroxyphenyl)bis(o-hydroxy)salen, 3,3'-(1e,1'e)-((1r,2s)-1,2-bis(2-hydroxyphenyl)ethane-1,2-diyl)bis(azan-1-yl-1-ylidene)bis(methan-1-yl-1-ylidene)dibenzene-1,2-diol)] |
CN102933216A (en) * | 2010-04-28 | 2013-02-13 | 株式会社Ihi | Anti-brain-tumor drug |
US20160023996A1 (en) * | 2012-09-28 | 2016-01-28 | Bose Institute | Cancer Chemotherapeutic Agent/Formulation, Manufacture and Use Thereof |
-
2017
- 2017-03-29 CN CN201710195193.4A patent/CN106831485A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6310721A (en) * | 1987-03-19 | 1988-01-18 | Rikagaku Kenkyusho | anticancer drug |
KR20100023679A (en) * | 2008-08-22 | 2010-03-04 | 건국대학교 산학협력단 | Use in anti-cancer agent of [(meso-bis(o-hydroxyphenyl)bis(o-hydroxy)salen, 3,3'-(1e,1'e)-((1r,2s)-1,2-bis(2-hydroxyphenyl)ethane-1,2-diyl)bis(azan-1-yl-1-ylidene)bis(methan-1-yl-1-ylidene)dibenzene-1,2-diol)] |
CN102933216A (en) * | 2010-04-28 | 2013-02-13 | 株式会社Ihi | Anti-brain-tumor drug |
US20160023996A1 (en) * | 2012-09-28 | 2016-01-28 | Bose Institute | Cancer Chemotherapeutic Agent/Formulation, Manufacture and Use Thereof |
Non-Patent Citations (5)
Title |
---|
FIONA N. -F. HOW等: "Synthesis and Characterization of Various Type of Azines as Potential Bioactive Agents", 《INTERNATIONAL PROCEEDINGS OF CHEMICAL, BIOLOGICAL & ENVIRONMENTAL ENGINEERING》 * |
JOHN REGLINSKI等: "N,N0-Bis(2-methoxybenzylidene) adducts of ethane-1,2-diamine, propane-1,3-diamine and butane-1,4-diamine", 《ACTA CRYSTALLOGRAPHICA SECTION C》 * |
V. E. KUZ’MIN等: "Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure", 《SAR AND QSAR IN ENVIRONMENTAL RESEARCH》 * |
XIAO-NA MA等: "Two families of bis(imido) symmetrical Schiff bases: X-ray crystal structure and optical properties", 《JOURNAL OF MOLECULAR STRUCTURE》 * |
姜凤超: "《药物设计学》", 31 May 2007 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104945302B (en) | The structure of the double Schiff bases of 3 indolecarboxaldehyde of benzil dihydrazone, preparation and use | |
CN107266348B (en) | Preparation, structure and application of biphenylphenone hydrazone-3-indole carboxaldehyde Schiff base | |
CN106543070A (en) | Carbazole amide-type room temperature phosphorimetry molecule that N replaces and its preparation method and application | |
CN104877674A (en) | Aqueous solution capable of generating white fluorescence through excitation and preparation method thereof | |
CN106866618A (en) | Two(The methylene of thiophene 2)The preparation and use of the diamines of butane 1,4 | |
CN104130269B (en) | A kind of sensitization discoloration material and its application in discoloration dress material | |
CN113121442B (en) | Synthesis method and application of spiro-substituted acridine compound | |
CN107266349B (en) | Preparation, structure and application of biphenylphenone hydrazone-2-indole carboxaldehyde Schiff base | |
CN106831485A (en) | Two(4 methoxybenzylidenes)The preparation and use of the diamines of butane 1,4 | |
CN106749167A (en) | Two(The methylene of thiophene 2)The preparation and use of the diamines of propane 1,3 | |
CN105348146B (en) | Structure, preparation and use of benzil hydrazone-chlorobenzaldehyde bis-Schiff base | |
CN107043345A (en) | Preparation, structure and the purposes of the diketone Schiff base of 4-acetylbiphenyl hydrazone indoline 2,3 | |
CN107118147B (en) | Preparation, structure and application of biphenylphenone hydrazone-3-acetylindosieffer base | |
CN106928090A (en) | Two(4 methoxybenzylidenes)The preparation and use of the diamines of propane 1,3 | |
CN106946735A (en) | Two(4 methoxybenzylidenes)The preparation and use of the diamines of dodecane 1,12 | |
CN104151194B (en) | The structure of benzil dihydrazone-N, N`-bis-(4-methoxyl group-1-formyl radical benzene), preparation and purposes | |
CN106866619A (en) | Two(The methylene of thiophene 2)The preparation and use of the diamines of dodecane 1,12 | |
CN105367445B (en) | Preparation, structure and application of benzyl dihydrazone-N-mono-(2-hydroxy-4-diethylin-1-formyl benzene) | |
CN110590765B (en) | Structure, preparation and application of 2-thiazole formaldehyde-furfural Schiff base | |
CN109824572B (en) | Structure, preparation and application of 4-hydroxybenzophenone hydrazone-1-methyl-3 indolecarboxaldehyde Schiff base | |
CN114478559B (en) | Solid-state light-stimulated fluorescence rapid color-changing material, and preparation method and application thereof | |
CN107033063B (en) | Preparation, structure and the purposes of 4-acetylbiphenyl hydrazone -4- indolecarboxaldehyde Schiff base | |
CN107043344B (en) | Preparation, structure and the purposes of 4-acetylbiphenyl hydrazone-N- methyl -3- indolecarboxaldehyde Schiff base | |
CN111153884A (en) | A class of π-system extended coumarin compounds, their preparation methods and their applications as photoluminescent materials | |
CN110407718B (en) | Benzimide Derivatives Using Triphenylamine as Donor and Their Preparation and Application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170613 |
|
RJ01 | Rejection of invention patent application after publication |